SMARCAL1: a new target for taming tumor immune evasion

Ting Xiao; Shiqi Li; Xinghua Long

doi:10.1002/mco2.730

MedComm ›› 2024, Vol. 5 ›› Issue (9) : e730 DOI: 10.1002/mco2.730

HIGHLIGHT

SMARCAL1: a new target for taming tumor immune evasion

Author information +

History +

PDF

Cite this article

Download citation ▾

Ting Xiao, Shiqi Li, Xinghua Long. SMARCAL1: a new target for taming tumor immune evasion. MedComm, 2024, 5(9): e730 DOI:10.1002/mco2.730

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Leuzzi G, Vasciaveo A, Taglialatela A, et al. SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell. 2024; 187(4): 861-881. e32.

[2]	Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020; 10(1): 26-39.

[3]	Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol. 2020; 21(9): 501-521.

[4]	Boerkoel CF, Takashima H, John J, et al. Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia. Nat Genet. 2002; 30(2): 215-220.

[5]	Sotiriou SK, Halazonetis TD. Remodeling collapsed DNA replication forks for cancer development. Cancer Res. 2019; 79(7): 1297-1298.

[6]	Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022; 20(1): 44.

[7]	Rakesh R, Chanana UB, Hussain S, et al. Altering mammalian transcription networking with ADAADi: an inhibitor of ATP-dependent chromatin remodeling. PLoS One. 2021; 16(5): e0251354.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.